Renal failure patients have an increased risk of infection, including skin and soft tissue infections. This increased susceptibility is multifactorial, due to the conditions causing the renal failure as well as complications of treatment and renal failure’s innate effects on patient health. These infections have a significant impact on patient morbidity, increased hospital and procedural demands, and the cost of health care. Many renal failure patients are seen regularly by their nephrology clinic caregivers due to the need for frequent dialysis and transplant monitoring. Familiarity with common skin and soft tissue infections by these caregivers allowing enhanced patient education, optimal infection prevention, and early recognition could significantly reduce the morbidity and cost of these disorders, such as diabetic foot syndrome, necrotizing fasciitis, and herpetic infections.

Keywords:
Cutaneous infection, Nephrology, Diabetes mellitus, Renal transplant
1.
Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B: Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008; 3: 1526–1533.
2.
Girndt M, Sester U, Sester M, Kaul H, Kohler H: Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 1999; 14: 2807–2810.
3.
Berman SJ, Johnson EW, Nakatsu C, Alkan M, Chen R, LeDuc J: Burden of infection in patients with end-stage renal disease requiring long-term dialysis. Clin Infect Dis 2004; 39; 1747–1753.
4.
Kokubo K, Kurihara Y, Kobayashi K, Tsukao H, Kobayashi H: Evaluation of the biocompatibility of dialysis membranes. Blood Purif 2015; 40: 293–297
5.
United States Renal Data System (USRDS): 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2017.
6.
Peleg AY, Weerarathna T, McCarthy JS, Davis TM: Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007; 23: 3–13.
7.
Casqueiro J, Casqueiro J, Alves C: Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab 2012; 16(suppl 1): S27–S36.
8.
Hobizal KB, Wukich DK: Diabetic foot infections: current concept review. Diabet Foot Ankle 2012; 3.
9.
Jackson LA: Evaluating diabetes mellitus as a risk factor for community-acquired infections. Clin Infect Dis 2005; 41: 289–290.
10.
Suaya JA, Eisenberg DF, Fang C, Miller LG: Skin and soft tissue infections and associated complications among commercially insured patients aged 0–64 years with and without diabetes in the U.S. PLoS One 2013; 8: e60057.
11.
Bakker K, Apelqvist J, Schaper NC; International Working Group on Diabetic Foot Editorial Board: Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev 2012; 28(suppl 1): 225–231.
12.
Wu SC, Driver VR, Wrobel JS, Armstrong DG: Foot ulcers in the diabetic patient, prevention and treatment. Vasc Health Risk Manag 2007; 3: 65–76.
13.
Pernat AM, Persic V, Usvyat L, Saunders L, Rogus J, Maddux FW, Lacson E Jr, Kotanko P: Implementation of routine foot check in patients with diabetes on hemodialysis: associations with outcomes. BMJ Open Diabetes Res Care 2016; 4: e000158.
14.
Armstrong DG, Lavery LA: Diabetic foot ulcers: prevention, diagnosis and classification. Am Fam Physician 1998; 57: 1325–1332.
15.
Chellan G, Shivaprakash S, Karimassery Ramaiyar S, Varma AK, Varma N, Thekkeparambil Sukumaran M, Rohinivilasam Vasukutty J, Bal A, Kumar H: Spectrum and prevalence of fungi infecting deep tissues of lower-limb wounds in patients with type 2 diabetes. J Clin Microbiol 2010; 48: 2097–2102.
16.
Gunderson CG, Martinello RA: A systematic review of bacteremias in cellulitis and erysipelas. J Infect 2012; 64: 148–155.
17.
Chennamsetty A, Khourdaji I, Burks F, Killinger KA: Contemporary diagnosis and management of fournier’s gangrene. Ther Adv Urol 2015; 7: 203–215.
18.
Narain U, Gupta A: Superficial fungal infections in and stage renal disease patients. Int J Adv Med 2016; 3: 1043–1047.
19.
Badiee P, Hashemizadeh Z: Opportunistic invasive fungal infections: diagnosis and clinical management. Indian J Med Res 2014; 139: 195–204.
20.
Dicle O, Parmaksizoglu B, Gurkan A, Tuncer M, Demirbas A, Yilmaz E: Skin infections in 401 renal transplant recipients in Southern Turkey. Exp Clin Transplant 2009; 7: 133–136.
21.
Sulowicz J, Wojas-Pelc A, Kuzniewski M, Ignacak E, Janda K, Sulowicz W: Cutaneous viral infections in patients after kidney transplantation: risk factors. Pol Arch Med Wewn 2013; 123: 686–692.
22.
Weikert BC, Blumberg EA: Viral infection after renal transplantation: surveillance and management. Clin J Am Soc Nephrol 2008; 3(suppl 2):S76–S86.
23.
Cukuranovic J, Ugrenovic S, Jovanovic I, Visnjic M, Stefanovic V: Viral infection in renal transplant recipients. ScientificWorldJournal 2012; 2012: 820621.
24.
Ulrich C, Hackethal M, Meyer T, Geusau A, Nindl I, Ulrich M, Forschner T, Sterry W, Stockfleth E: Skin infections in organ transplant recipients. J Dtsch Dermatol Ges 2008; 6: 98–105.
25.
Campistol JM, Schena FP: Kaposi’s sarcoma in renal transplant recipients – the impact of proliferation signal inhibitors. Nephrol Dial Transplant 2007; 22(suppl 1):i17–i22.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.